China Temporarily Bans Certain Foreigners From Entry
Client Alert | 1 min read | 03.27.20
On March 26, 2020, the Ministry of Foreign Affairs of the People’s Republic of China (“MFA”) announced a decision to temporarily suspend entry into China by foreign nationals holding valid visas or residence permits (including APEC Business Travel Cards) as a preventative measure against the COVID-19 pandemic starting from midnight, March 28, 2020.
The announcement lists the specific categories of visas affected (above). However, those who enter with the visas listed below will not be affected:
- Diplomatic, service, courtesy or C visas.
- Entry with new visas, specifically those issued after this announcement.
Meanwhile, the MFA has confirmed that foreign nationals affected may apply for new visas at Chinese embassies or consulates for necessary economic, trade, scientific or technological activities or based on emergency humanitarian need.
The announcement does not indicate the expiration date of the suspension. According to the MFA, the suspension is a temporary measure that China is compelled to take considering the pandemic and the varied practices of other countries. The measures will be calibrated in view of the evolving situation and revised or updated accordingly.
Because some employees with valid work permits may not be able to enter China from March 28 due to the suspension, employers will need to prepare to make alternative work arrangements for expat workers who may be trying to return to China.
For the text of the official announcement from MFA, please go to:
Contacts
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today